Esperion Therapeutics (NASDAQ: ESPR) presented data from a Phase 2 study of bempedoic acid in children and a secondary analysis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE